Revolution Medicines (RVMD) expects full year 2026 GAAP operating expenses to be between $1.6 and $1.7 billion, which includes estimated non-cash stock-based compensation expense of between $180 and $200 million.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines initiated with an Outperform at Evercore ISI
- Is RVMD a Buy, Before Earnings?
- Revolution Medicines placed on ‘Positive Catalyst Watch’ at JPMorgan
- Revolution Medicines put volume heavy and directionally bearish
- Revolution Medicines price target raised to $122 from $92 at JPMorgan